Relmada Therapeutics (RLMD) Interest & Investment Income (2014 - 2026)
Relmada Therapeutics (RLMD) posted quarterly Interest & Investment Income of $959762.0 for Q1 2026, up 117.99% year-over-year from $440287.0 in Q1 2025, and up 147.85% quarter-over-quarter from $387231.0 in Q4 2025.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Interest & Investment Income (2014 - 2026) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Interest & Investment Income for 8 consecutive years, with $959762.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 117.99% year-over-year to $959762.0; the TTM figure through Mar 2026 stood at $1.9 million (down 34.28% YoY), while the FY2025 annual figure was $1.4 million, down 60.45% from the prior year.
- Interest & Investment Income advanced to $959762.0 in Q1 2026 per RLMD's latest filing, from $387231.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.4 million in Q2 2023 and bottomed at $247013.0 in Q3 2025.
- Historically, Interest & Investment Income has averaged $849036.6 across 4 years, with a median of $959762.0 in 2026.
- Annual changes were most pronounced in 2025 — Interest & Investment Income plunged 71.16% — and 2026, when it jumped 117.99%.
- Relmada Therapeutics' Interest & Investment Income stood at $1.3 million in 2023, then tumbled by 48.01% to $654642.0 in 2024, then plunged by 40.85% to $387231.0 in 2025, then jumped by 147.85% to $959762.0 in 2026.
- Business Quant data shows RLMD's Interest & Investment Income at $959762.0 in Q1 2026, $387231.0 in Q4 2025, and $247013.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - | 2.30 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 959,762.00 |
| Dec 31, 2025 | 387,231.00 |
| Sep 30, 2025 | 247,013.00 |
| Jun 30, 2025 | 321,458.00 |
| Mar 31, 2025 | 440,287.00 |
| Dec 31, 2024 | 654,642.00 |
| Sep 30, 2024 | 856,478.00 |
| Jun 30, 2024 | 963,013.00 |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 1.26 Mn |
| Sep 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.36 Mn |
| Mar 31, 2023 | 1.21 Mn |
| Sep 30, 2020 | 363,300.00 |
| Jun 30, 2020 | 404,004.00 |
| Sep 30, 2019 | 66,965.00 |
| Jun 30, 2019 | 29,049.00 |
| Mar 31, 2018 | -397,111.00 |
| Dec 31, 2017 | -311,871.00 |